<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVE: To date, there are no reliable data regarding the actual treatment received by women with refractory obstetric <z:e sem="disease" ids="C0085278" disease_type="Disease or Syndrome" abbrv="">antiphospholipid syndrome</z:e> (OAPS) </plain></SENT>
<SENT sid="1" pm="."><plain>The aim of this study was to assess current clinical evidence and new trends in the treatment of refractory OAPS </plain></SENT>
<SENT sid="2" pm="."><plain>METHODS: A non-systematic but comprehensive literature search using relevant keywords was made to identify relevant articles published in English from different computerized databases: PubMed (Medline), Google Scholar electronic database search and The Cochrane Library, from January 2000 to March 2012 </plain></SENT>
<SENT sid="3" pm="."><plain>Studies on the treatment of poor obstetric outcomes in women with OAPS were included </plain></SENT>
<SENT sid="4" pm="."><plain>Prospective randomized clinical trials, cohort studies, reviews, systematic reviews and meta-analysis were retrieved </plain></SENT>
<SENT sid="5" pm="."><plain>RESULTS: A total of 130 articles were finally selected for this review, including 17 randomized clinical trials and four meta-analyses </plain></SENT>
<SENT sid="6" pm="."><plain>The majority of articles were non-randomized original papers and basic and clinical reviews </plain></SENT>
<SENT sid="7" pm="."><plain>CONCLUSION: Up to 20% of women with OAPS do not receive the currently recommended therapeutic regimen </plain></SENT>
<SENT sid="8" pm="."><plain>Unfortunately, well-designed studies regarding the usefulness of new drugs in refractory OAPS are scarce </plain></SENT>
<SENT sid="9" pm="."><plain>Hydroxychloroquine and low-dose <z:chebi fb="2" ids="8378">prednisolone</z:chebi> appear to be useful when added to standard therapy </plain></SENT>
<SENT sid="10" pm="."><plain>Current data do not support the use of intravenous immunoglobulins in this field </plain></SENT>
<SENT sid="11" pm="."><plain>The role played by double anti-aggregant therapy, fondaparinux, <z:chebi fb="27" ids="27300">vitamin D</z:chebi>, pentoxifylline and TNF-targeted therapies should be tested in well-designed studies </plain></SENT>
</text></document>